15 results on '"Ellin, Fredrik"'
Search Results
2. Impact of comorbidity in elderly patients with peripheral T-cell lymphoma: an international retrospective analysis of 891 patients
- Author
-
Mead, Monica, Cederleuf, Henrik, Björklund, Maja, Wang, Xiaoyan, Relander, Thomas, Jerkeman, Mats, Gaut, Daria, Larson, Sarah, and Ellin, Fredrik
- Subjects
Biomedical and Clinical Sciences ,Cardiovascular Medicine and Haematology ,Clinical Sciences ,Oncology and Carcinogenesis ,Cancer ,Clinical Research ,Lymphoma ,Aging ,Rare Diseases ,Hematology ,Aged ,Cohort Studies ,Comorbidity ,Humans ,Lymphoma ,T-Cell ,Peripheral ,Retrospective Studies ,Cardiovascular medicine and haematology - Abstract
Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of aggressive neoplasms with poor outcomes, commonly affecting older patients with comorbidities. This study aims to describe outcomes of older patients with PTCL in a large international cohort. Patients aged ≥70 years with PTCL diagnosed from 1 January 2010 to 31 December 2015 in the Swedish Lymphoma Registry (SLR) and California Cancer Registry (CCR) were identified. Data on comorbidity were retrospectively collected according to the Charlson Comorbidity Index (CCI), and clinical outcomes were extracted. A total of 891 patients were included (SLR, n = 173; CCR, n = 718). Median age was 77 (SLR) and 78 (CCR) years. Included subtypes were as follows: angioimmunoblastic T-cell lymphoma, n = 226; anaplastic large-cell lymphoma, n = 122; enteropathy-associated T-cell lymphoma (EATL), n = 31; hepatosplenic TCL, n = 7; natural killer-/T-cell lymphoma, n = 62; PTCL not otherwise specified, n = 443. CCI data were available in 775 patients (87%), and CCI scores were divided into the groups CCI = 0 (39%), CCI = 1 (22%), and CCI > 1 (39%). Median age did not differ among the CCI groups (P = .72). Patients with a CCI > 1 had a worse median overall survival (4.4 months) compared with patients with CCI = 0 (11.9 months) and CCI = 1 (8.4 months; P < .001). Comorbidity and advancing age in as little as 5-year increments are important adverse factors in this group. Most patients died of lymphoma within a year from diagnosis, underscoring the importance of developing new treatments.
- Published
- 2022
3. Impact of comorbidity in older patients with peripheral T-cell lymphoma: an international retrospective analysis of 891 patients
- Author
-
Mead, Monica, Cederleuf, Henrik, Björklund, Maja, Wang, Xiaoyan, Relander, Thomas, Jerkeman, Mats, Gaut, Daria, Larson, Sarah, and Ellin, Fredrik
- Published
- 2022
- Full Text
- View/download PDF
4. Nationwide Assessment of Patient Trajectories in Mantle Cell Lymphoma: The Swedish MCLcomplete Project
- Author
-
Jerkeman, Mats, primary, Ekberg, Sara, additional, Glimelius, Ingrid, additional, Albertsson-Lindblad, Alexandra, additional, Entrop, Joshua P., additional, Ellin, Fredrik, additional, Sonnevi, Kristina, additional, Lewerin, Catharina, additional, Brandefors, Lena, additional, and Smedby, Karin E., additional
- Published
- 2023
- Full Text
- View/download PDF
5. Idelalisib (PI3Kδ inhibitor) therapy for patients with relapsed/refractory chronic lymphocytic leukemia: A Swedish nation-wide real-world report on consecutively identified patients.
- Author
-
Mattsson, Agnes, Sylvan, Sandra Eketorp, Axelsson, Per, Ellin, Fredrik, Kjellander, Christian, Larsson, Karin, Lauri, Birgitta, Lewerin, Catharina, Scharenberg, Christian, Tätting, Love, Johansson, Hemming, Österborg, Anders, and Hansson, Lotta
- Subjects
CHRONIC lymphocytic leukemia ,FLUDARABINE ,CHRONIC leukemia ,PATIENT experience ,PROGRESSION-free survival ,SALVAGE therapy - Abstract
Objectives: We examined the efficacy and toxicity of the PI3Kδ inhibitor idelalisib in combination with rituximab salvage therapy in consecutively identified Swedish patients with chronic lymphocytic leukemia (CLL). Methods and Results: Thirty-seven patients with relapsed/refractory disease were included. The median number of prior lines of therapy was 3 (range 1-11); the median age was 69 years (range 50-89); 22% had Cumulative Illness Rating Scale (CIRS) >6 and 51% had del(17p)/TP53 mutation. The overall response rate was 65% (all but one was partial response [PR]). The median duration of therapy was 9.8 months (range 0.9-44.8). The median progression-free survival was 16.4 months (95% CI: 10.4-26.3) and median overall survival had not been reached (75% remained alive at 24 months of follow-up). The most common reason for cessation of therapy was colitis (n = 8, of which seven patients experienced grade ≥3 colitis). The most common serious adverse event was grade ≥3 infection, which occurred in 24 patients (65%). Conclusions: Our real-world results suggest that idelalisib is an effective and relatively safe treatment for patients with advanced-stage CLL when no other therapies exist. Alternative dosing regimens and new PI3K inhibitors should be explored, particularly in patients who are double-refractory to inhibitors of BTK and Bcl-2. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
6. Nationwide Assessment of Patient Trajectories in Mantle Cell Lymphoma : The Swedish MCLcomplete Project
- Author
-
Jerkeman, Mats, Ekberg, Sara, Glimelius, Ingrid, Albertsson-Lindblad, Alexandra, Entrop, Joshua P., Ellin, Fredrik, Sonnevi, Kristina, Lewerin, Catharina, Brandefors, Lena, Smedby, Karin E., Jerkeman, Mats, Ekberg, Sara, Glimelius, Ingrid, Albertsson-Lindblad, Alexandra, Entrop, Joshua P., Ellin, Fredrik, Sonnevi, Kristina, Lewerin, Catharina, Brandefors, Lena, and Smedby, Karin E.
- Abstract
Mantle cell lymphoma (MCL) is a B-cell malignancy currently considered incurable. Although some patients obtain prolonged remission after first-line chemoimmunotherapy, many will need several treatment lines. Here, we present a nationwide assessment of treatment strategies, time to progression and survival in MCL. All patients diagnosed with MCL 2006-2018 were identified in the Swedish Lymphoma Register. Information on all lines of therapy was extracted from the medical records. Overall and progression-free survival (OS and PFS) were assessed through August 2021. In total, 1367 patients were included (median age, 71 years) and median follow-up was 6.8 years. Two hundred and one (15%) were managed initially with watch-and-wait, but 1235 (90%) eventually received treatment. The most frequently used first-line regimens were rituximab-bendamustine (BR) (n = 368; 30%) and Nordic MCL2 (n = 342; 28%). During follow-up, 630 patients (46%) experienced relapse/progression and 546 (40%) received second-line treatment. The most frequently used second-line regimen was BR (n = 185; 34%) but otherwise a wide variety of second-line treatments were used. Further, 382 and 228 patients experienced a second or third relapse/progression, respectively. Median PFS after first (PFS-1), second (PFS-2), third (PFS-3), and fourth (PFS-4) treatment lines was 29.4, 8.9, 4.3, and 2.7 months. Patients with early progression, defined as a PFS-1 <24 months, had an inferior median OS of 13 versus 37 months in patients with later relapse. For patients treated with frontline BR, however, time to relapse had no impact on later outcome. By use of nationwide population-based data, we provide important benchmarks for future studies of all treatment lines in MCL.
- Published
- 2023
- Full Text
- View/download PDF
7. Idelalisib (PI3K delta inhibitor) therapy for patients with relapsed/refractory chronic lymphocytic leukemia: A Swedish nation-wide real-world report on consecutively identified patients
- Author
-
Mattsson, Agnes, Sylvan, Sandra Eketorp, Axelsson, Per, Ellin, Fredrik, Kjellander, Christian, Larsson, Karin, Lauri, Birgitta, Lewerin, Catharina, Scharenberg, Christian, Tätting, Love, Johansson, Hemming, Osterborg, Anders, Hansson, Lotta, Mattsson, Agnes, Sylvan, Sandra Eketorp, Axelsson, Per, Ellin, Fredrik, Kjellander, Christian, Larsson, Karin, Lauri, Birgitta, Lewerin, Catharina, Scharenberg, Christian, Tätting, Love, Johansson, Hemming, Osterborg, Anders, and Hansson, Lotta
- Abstract
Objectives: We examined the efficacy and toxicity of the PI3K delta inhibitor idelalisib in combination with rituximab salvage therapy in consecutively identified Swedish patients with chronic lymphocytic leukemia (CLL). Methods and Results: Thirty-seven patients with relapsed/refractory disease were included. The median number of prior lines of therapy was 3 (range 1-11); the median age was 69 years (range 50-89); 22% had Cumulative Illness Rating Scale (CIRS) >6 and 51% had del(17p)/TP53 mutation. The overall response rate was 65% (all but one was partial response [PR]). The median duration of therapy was 9.8 months (range 0.9-44.8). The median progression-free survival was 16.4 months (95% CI: 10.4-26.3) and median overall survival had not been reached (75% remained alive at 24 months of follow-up). The most common reason for cessation of therapy was colitis (n = 8, of which seven patients experienced grade =3 colitis). The most common serious adverse event was grade =3 infection, which occurred in 24 patients (65%). Conclusions: Our real-world results suggest that idelalisib is an effective and relatively safe treatment for patients with advanced-stage CLL when no other therapies exist. Alternative dosing regimens and new PI3K inhibitors should be explored, particularly in patients who are double-refractory to inhibitors of BTK and Bcl-2., Funding Agencies|AFA Forsakring [130054]; Cancer Society in Stockholm; Felix Mindus Foundation; Gilead Sciences Nordic Fellowship Program; Insamlingsstiftelsen Cancer- och Allergifonden; Karolinska Institutet Foundations; King Gustaf V Jubilee Fund; Senior Clinical Research Position (SLL/KI) [K2894-2016]; Stockholm County Council (SLL/ALF) [20150070]; Swedish Cancer Society [150930, 160534]
- Published
- 2023
- Full Text
- View/download PDF
8. Outcome of limited-stage peripheral T-Cell lymphoma after CHOP(−like) therapy:A population based study of 239 patients from the Nordic lymphoma epidemiology group
- Author
-
Ludvigsen Al-Mashhadi, Ahmed, Cederleuf, Henrik, Kuhr Jensen, Rasmus, Holm Nielsen, Torsten, Bjerregård Pedersen, Martin, Bech Mortensen, Thomas, Relander, Thomas, Jerkeman, Mats, Gang, Anne Ortved, Kristensen, Anne Louise, Roost Clausen, Michael, Brown, Peter de Nully, Tang Severinsen, Marianne, Jakobsen, Lasse Hjort, Ellin, Fredrik, El-Galaly, Tarec Christoffer, Ludvigsen Al-Mashhadi, Ahmed, Cederleuf, Henrik, Kuhr Jensen, Rasmus, Holm Nielsen, Torsten, Bjerregård Pedersen, Martin, Bech Mortensen, Thomas, Relander, Thomas, Jerkeman, Mats, Gang, Anne Ortved, Kristensen, Anne Louise, Roost Clausen, Michael, Brown, Peter de Nully, Tang Severinsen, Marianne, Jakobsen, Lasse Hjort, Ellin, Fredrik, and El-Galaly, Tarec Christoffer
- Abstract
Peripheral T-Cell Lymphomas (PTCLs) are rare, aggressive lymphomas with poor outcomes, but limited-stage disease is infrequent and not well-described. This study reports outcomes and prognostic factors in limited-stage nodal PTCLs in a binational population-based setting. Patients were identified from the Danish and Swedish lymphoma registries. Adults diagnosed with limited-stage nodal PTCL (stage I-II) and treated with CHOP(−like) therapy ±radiotherapy between 2000 and 2014 were included. Medical records were reviewed by local investigators. A total of 239 patients with a median age of 62 years were included; 67% received 6–8 cycles of CHOP(−like) therapy and 22% received 3–4 cycles, of which 59% also received radiotherapy. Autologous stem cell transplant consolidation was administered to 16% of all patients. Median follow-up was 127 months with 5-years overall survival (OS) of 58% (95% CI: 53–65) and progression-free survival (PFS) of 53% (95% CI: 47–59). In multivariable analysis, age ≥ 60 years and B-symptoms were unfavorable and ALK+ anaplastic large cell T-Cell lymphoma was favorable for survival outcomes. There was no difference in treatment-specific outcome (3–4 cycles vs. 6–8 cycles of CHOP(−like) ± radiotherapy). Low-risk patients (age < 60 without B-symptoms) had a 5-year OS of 77% (95% CI 67–89%). In the present study of limited-stage nodal PTCL, survival after curative intent chemotherapy +/− radiotherapy was inferior to that of limited-stage diffuse large B-cell lymphoma, but a subgroup of young patients without B-symptoms had very good outcomes. Treatment outcomes after 3–4 cycles versus 6–8 cycles of CHOP(−like) therapy were comparable.
- Published
- 2023
9. Outcome of limited‐stage peripheral T‐Cell lymphoma after CHOP (−like) therapy: A population based study of 239 patients from the Nordic lymphoma epidemiology group
- Author
-
Ludvigsen Al‐Mashhadi, Ahmed, primary, Cederleuf, Henrik, additional, Kuhr Jensen, Rasmus, additional, Holm Nielsen, Torsten, additional, Bjerregård Pedersen, Martin, additional, Bech Mortensen, Thomas, additional, Relander, Thomas, additional, Jerkeman, Mats, additional, Ortved Gang, Anne, additional, Kristensen, Anne Louise, additional, Roost Clausen, Michael, additional, de Nully Brown, Peter, additional, Tang Severinsen, Marianne, additional, Jakobsen, Lasse Hjort, additional, Ellin, Fredrik, additional, and El‐Galaly, Tarec Christoffer, additional
- Published
- 2023
- Full Text
- View/download PDF
10. Long-Term Follow-up of Clinical Outcome Determinants and Correlative Biological Features from the Nordic NLG-T-01 Trial
- Author
-
Relander, Thomas, primary, Pedersen, Martin Bjerregård, additional, Ellin, Fredrik, additional, Lauritzsen, Grete Fossum, additional, Jantunen, Esa, additional, Hagberg, Hans, additional, Holte, Harald, additional, Österborg, Anders, additional, Brown, Peter De Nully, additional, Kuittinen, Outi, additional, Erlanson, Martin, additional, Ostenstad, Bjorn, additional, Fagerli, Unn-Merete, additional, Delabie, Jan, additional, Sundström, Christer, additional, Sander, Birgitta, additional, Hamilton-Dutoit, Stephen, additional, Ehinger, Mats, additional, Liestol, Knut, additional, Toldbod, Helle, additional, Feldman, Andrew L., additional, and d'Amore, Francesco Annibale, additional
- Published
- 2022
- Full Text
- View/download PDF
11. CNS Relapse in T-Cell Lymphoma Index: A Risk Score to Predict Central Nervous System Relapse in Patients with T-Cell Lymphomas
- Author
-
Bhansali, Rahul S., primary, Ellin, Fredrik, additional, Cao, Miao, additional, Relander, Thomas, additional, Li, Wenrui, additional, Long, Qi, additional, Ganesan, Nivetha, additional, Stuver, Robert, additional, Horwitz, Steven M., additional, Wudhikarn, Kitsada, additional, Hwang, Steven R, additional, Bennani, N. Nora, additional, Chavez, Julio C., additional, Sokol, Lubomir, additional, Saeed, Hayder, additional, Duan, Frank, additional, Porcu, Pierluigi, additional, Pullarkat, Priyanka, additional, Mehta-Shah, Neha, additional, Zain, Jasmine, additional, Ruiz, Miguel, additional, Brammer, Jonathan E, additional, Prakash, Rishab, additional, Iyer, Swami P., additional, Olszewski, Adam J., additional, Major, Ajay, additional, Smith, Sonali M., additional, Riedell, Peter A., additional, Goldin, Caroline, additional, Haverkos, Bradley M., additional, Hu, Bei, additional, Allen, Pamela B., additional, Toama, Wael, additional, Janakiram, Murali, additional, Brooks, Taylor, additional, Jagadeesh, Deepa, additional, Hariharan, Nisha, additional, Goodman, Aaron M, additional, Ghione, Paola, additional, Fayyaz, Fatima, additional, Rhodes, Joanna M., additional, Chong, Elise A., additional, Gerson, James N., additional, Landsburg, Daniel J., additional, Dwivedy Nasta, Sunita, additional, Schuster, Stephen J., additional, Svoboda, Jakub, additional, Jerkeman, Mats, additional, and Barta, Stefan K., additional
- Published
- 2022
- Full Text
- View/download PDF
12. Outcome of limited‐stage peripheral T‐Cell lymphoma after CHOP(−like) therapy: A population based study of 239 patients from the Nordic lymphoma epidemiology group.
- Author
-
Ludvigsen Al‐Mashhadi, Ahmed, Cederleuf, Henrik, Kuhr Jensen, Rasmus, Holm Nielsen, Torsten, Bjerregård Pedersen, Martin, Bech Mortensen, Thomas, Relander, Thomas, Jerkeman, Mats, Ortved Gang, Anne, Kristensen, Anne Louise, Roost Clausen, Michael, de Nully Brown, Peter, Tang Severinsen, Marianne, Jakobsen, Lasse Hjort, Ellin, Fredrik, and El‐Galaly, Tarec Christoffer
- Published
- 2023
- Full Text
- View/download PDF
13. The National Swedish Lymphoma Register - a systematic validation of data quality.
- Author
-
Ekström Smedby K, Eloranta S, Wästerlid T, Falini V, Jerlström U, Ellin F, Papworth K, Westerberg J, Lewerin C, Andersson PO, Lind Kristjansdottir H, Brandefors L, Mörth C, Hallén K, Kuric N, Abu Sabaa A, Wahlin BE, Molin D, Enblad G, Hörstedt AS, Jerkeman M, and Glimelius I
- Subjects
- Humans, Sweden epidemiology, Male, Female, Adult, Middle Aged, Aged, Quality of Health Care standards, Registries statistics & numerical data, Lymphoma therapy, Lymphoma epidemiology, Lymphoma diagnosis, Data Accuracy
- Abstract
Background and Purpose: The Swedish Lymphoma Register (SLR) was initiated in the year 2000 with the aim to monitor quality of care in diagnostics, treatment and outcome of all lymphomas diagnosed nationally among adults. Here, we present the first systematic validation of SLR records as a basis for improved register quality and patient care., Patients and Methods: We evaluated timeliness and completeness of register records among patients diagnosed with lymphoma in the SLR (n = 16,905) compared with the National Cancer Register for the period 2013-2020. Comparability was assessed through evaluation of coding routines against national and international guidelines. Accuracy of 42 variables was evaluated through re-abstraction of data from medical records among 600 randomly selected patients diagnosed in 2016-2017 and treated across all six Swedish healthcare regions. Results: Completeness was high, >95% per year for the period 2013-2018, and >89% for 2019-2020 compared to the National Cancer Register. One in four patients was registered within 3 months, and 89.9% within 2 years of diagnosis. Registration instructions and coding procedures followed the prespecified guidelines. Missingness was generally low (<5%), but high for occasional variables, for example, those describing maintenance and consolidative treatment. Exact agreement of categorical variables was high overall (>80% for 24/34 variables), especially for treatment-related data (>80% for 17/19 variables)., Interpretation: Completeness and accuracy are high in the SLR, while timeliness could be improved. Finetuning of variable registration guided by this validation can further improve reliability of register reports and advance service to lymphoma patients and health care in the future.
- Published
- 2024
- Full Text
- View/download PDF
14. Nationwide Assessment of Patient Trajectories in Mantle Cell Lymphoma: The Swedish MCL complete Project.
- Author
-
Jerkeman M, Ekberg S, Glimelius I, Albertsson-Lindblad A, Entrop JP, Ellin F, Sonnevi K, Lewerin C, Brandefors L, and Smedby KE
- Abstract
Mantle cell lymphoma (MCL) is a B-cell malignancy currently considered incurable. Although some patients obtain prolonged remission after first-line chemoimmunotherapy, many will need several treatment lines. Here, we present a nationwide assessment of treatment strategies, time to progression and survival in MCL. All patients diagnosed with MCL 2006-2018 were identified in the Swedish Lymphoma Register. Information on all lines of therapy was extracted from the medical records. Overall and progression-free survival (OS and PFS) were assessed through August 2021. In total, 1367 patients were included (median age, 71 years) and median follow-up was 6.8 years. Two hundred and one (15%) were managed initially with watch-and-wait, but 1235 (90%) eventually received treatment. The most frequently used first-line regimens were rituximab-bendamustine (BR) (n = 368; 30%) and Nordic MCL2 (n = 342; 28%). During follow-up, 630 patients (46%) experienced relapse/progression and 546 (40%) received second-line treatment. The most frequently used second-line regimen was BR (n = 185; 34%) but otherwise a wide variety of second-line treatments were used. Further, 382 and 228 patients experienced a second or third relapse/progression, respectively. Median PFS after first (PFS-1), second (PFS-2), third (PFS-3), and fourth (PFS-4) treatment lines was 29.4, 8.9, 4.3, and 2.7 months. Patients with early progression, defined as a PFS-1 <24 months, had an inferior median OS of 13 versus 37 months in patients with later relapse. For patients treated with frontline BR, however, time to relapse had no impact on later outcome. By use of nationwide population-based data, we provide important benchmarks for future studies of all treatment lines in MCL., Competing Interests: MJ: Honoraria: Kite/Gilead, Janssen, Abbvie, AstraZeneca, Pierre Fabre, Roche, Genmab, MSD. Research support: Roche, Abbvie, AstraZeneca, BMS, Janssen. IG: Honoraria: Janssen, Takeda. Research support: Lokon Pharma. All the other authors have no conflicts of interest to disclose., (Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association.)
- Published
- 2023
- Full Text
- View/download PDF
15. Outcome of limited-stage peripheral T-Cell lymphoma after CHOP(-like) therapy: A population based study of 239 patients from the Nordic lymphoma epidemiology group.
- Author
-
Ludvigsen Al-Mashhadi A, Cederleuf H, Kuhr Jensen R, Holm Nielsen T, Bjerregård Pedersen M, Bech Mortensen T, Relander T, Jerkeman M, Ortved Gang A, Kristensen AL, Roost Clausen M, de Nully Brown P, Tang Severinsen M, Jakobsen LH, Ellin F, and El-Galaly TC
- Subjects
- Adult, Humans, Middle Aged, Antineoplastic Combined Chemotherapy Protocols adverse effects, Treatment Outcome, Stem Cell Transplantation, Doxorubicin, Prednisone adverse effects, Vincristine, Cyclophosphamide, Lymphoma, T-Cell, Peripheral drug therapy, Lymphoma, Large B-Cell, Diffuse drug therapy, Lymphoma, Large-Cell, Anaplastic
- Abstract
Peripheral T-Cell Lymphomas (PTCLs) are rare, aggressive lymphomas with poor outcomes, but limited-stage disease is infrequent and not well-described. This study reports outcomes and prognostic factors in limited-stage nodal PTCLs in a binational population-based setting. Patients were identified from the Danish and Swedish lymphoma registries. Adults diagnosed with limited-stage nodal PTCL (stage I-II) and treated with CHOP(-like) therapy ±radiotherapy between 2000 and 2014 were included. Medical records were reviewed by local investigators. A total of 239 patients with a median age of 62 years were included; 67% received 6-8 cycles of CHOP(-like) therapy and 22% received 3-4 cycles, of which 59% also received radiotherapy. Autologous stem cell transplant consolidation was administered to 16% of all patients. Median follow-up was 127 months with 5-years overall survival (OS) of 58% (95% CI: 53-65) and progression-free survival (PFS) of 53% (95% CI: 47-59). In multivariable analysis, age ≥ 60 years and B-symptoms were unfavorable and ALK+ anaplastic large cell T-Cell lymphoma was favorable for survival outcomes. There was no difference in treatment-specific outcome (3-4 cycles vs. 6-8 cycles of CHOP(-like) ± radiotherapy). Low-risk patients (age < 60 without B-symptoms) had a 5-year OS of 77% (95% CI 67-89%). In the present study of limited-stage nodal PTCL, survival after curative intent chemotherapy +/- radiotherapy was inferior to that of limited-stage diffuse large B-cell lymphoma, but a subgroup of young patients without B-symptoms had very good outcomes. Treatment outcomes after 3-4 cycles versus 6-8 cycles of CHOP(-like) therapy were comparable., (© 2023 The Authors. American Journal of Hematology published by Wiley Periodicals LLC.)
- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.